Dynavax Technologies Corporation (DVAX)
Days of sales outstanding (DSO)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Receivables turnover | — | — | — | — | — | |
DSO | days | — | — | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —
Based on the provided data, Dynavax Technologies Corporation has not disclosed its days of sales outstanding (DSO) for the years ending on December 31, 2020 through December 31, 2024. Consequently, without information on the DSO figure, it is challenging to assess the efficiency of the company in collecting its accounts receivable and managing its cash flow from sales within a specific timeframe. Monitoring DSO over time could provide insights into the company's credit policies, collection effectiveness, and potential liquidity issues.
Peer comparison
Dec 31, 2024
Company name
Symbol
DSO
Dynavax Technologies Corporation
DVAX
—
Abbott Laboratories
ABT
—
AbbVie Inc
ABBV
—
ACADIA Pharmaceuticals Inc
ACAD
—
Alkermes Plc
ALKS
90.15
Amphastar P
AMPH
67.96
ANI Pharmaceuticals Inc
ANIP
—
Arcus Biosciences Inc
RCUS
7.07
Biomarin Pharmaceutical Inc
BMRN
84.73
Bristol-Myers Squibb Company
BMY
81.21
Catalyst Pharmaceuticals Inc
CPRX
—